The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Over the past 50 years, dengue has spread from nine to over a hundred countries, making it the most rapidly spreading vector-borne disease. Yet, dengue continues to have a low profile among policy-makers and donors and does not receive the media attention it deserves. While there is no vaccine or cu...re for dengue, it can be managed and prevented. We need a renewed commitment to integrated programming that includes improved management and diagnosis, increased awareness and community participation in controlling the vector and enhanced environmental sanitation
more
This field action guide focuses on the first psychosocial assessment to be conducted just after a calamity strikes or just after a major event in an ongoing armed conflict. While it is necessary to update that initial assessment as the emergency situation evolves through the different phases of reco...very (briefly outlined in the “phase chart”), this mini book is meant to guide the formation of a team to assess the psychosocial as well as physical needs of children, their families and the communities and then the recommendations the team makes for ensuing support.
more
Act 851 | AN ACT to revise and consolidate the law relating to public health to
prevent disease, promote, safeguard, maintain and protect the health
of humans and animals and to provide for related matters.
Practical Guideline for collaborative interventions
The revised guidelines present two major changes to existing guidelines: (A) there are now just 2 categories of pneumonia instead of 3 (“pneumonia” which is treated at home with oral amoxicillin and “severe pneumonia” which requires injectable antibiotics) and (B) oral amoxicillin replaces o...ral cotrimoxazole as first line treatment, preferably in 250mg dispersible tablet form, twice daily for five days which can be reduced to three days in low HIV settings.
more
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z